Travere Therapeutics
TVTX
TVTX
114 hedge funds and large institutions have $753M invested in Travere Therapeutics in 2017 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 48 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
114
Holders Change
-7
Holders Change %
-5.79%
% of All Funds
2.84%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.1%
New
17
Increased
39
Reduced
48
Closed
16
Calls
$7.44M
Puts
$1.15M
Net Calls
+$6.28M
Net Calls Change
-$10M
Top Buyers
| 1 |
BlackRock
New York
|
+$57.7M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$14.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.89M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$7.78M |
Top Sellers
| 1 |
CCM
Consonance Capital Management
New York
|
-$11.8M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$7.83M |
| 3 |
BC
Broadfin Capital
New York
|
-$6.96M |
| 4 |
Jennison Associates
New York
|
-$5.3M |
| 5 |
Millennium Management
New York
|
-$4.58M |
